Scientists examine kids’ unique immune systems as more fall victim to covid
Eighteen months into the covid-19 pandemic, with the delta variant fueling a massive resurgence of disease, many hospitals are hitting a heartbreaking new low. They're now losing babies to the coronavirus. The first reported...
New tool harnesses immune cells from tumors to effectively fight cancer
Northwestern scientists have developed a new tool to harness immune cells from tumors to fight cancer rapidly and effectively, published in the journal Nature Biomedical Engineering. Their findings showed a dramatic shrinkage in tumors...
Transcription Factors Driving CAR T Cell Dysfunction
Broadcast Date: September 9, 2022Time: 9:00 am PT, 12:00 pm ET, 18:00 CET
REGISTER NOW
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological malignancies. Yet, it remains ineffective in solid...
Are Organoids the Future of Drug Discovery?
Broadcast Date: March 15, 2023Time: 9:00 am PT, 12:00 pm ET, 17:00 CET
REGISTER NOW
The organoid field has come a long way in a relatively a short amount of time. Although the field started...
GTC 2024: Nvidia Highlights AI ‘Revolution’ in Drug Discovery, Genomics
SAN JOSE, CA—Just as users train artificial intelligence (AI) models to search for a druggable target or predict the structure of a protein, so Nvidia founder and CEO Jensen Huang says he trained himself...
Assistant/Associate Professor in Bioproducts Biotechnology job with UNIVERSITY OF BRITISH COLUMBIA | 280739 –...
University of British Columbia ...
Nanomaterial Targets Obesity, Shrinks Local Fat Depots by Rejuvenating Healthy, “Dwarf” Adipocytes
Two studies reported separately by researchers at Columbia Engineering and Columbia University Irving Medical Center (CUIMC) demonstrate a new approach to obesity treatment that uses a positively charged cationic nanomaterial, PAMAM generation 3 (P-G3),...
StockWatch: FTC vs. Amgen-Horizon Could Slam Brakes on Biotech M&A
News that federal regulators will oppose Amgen (AMGN)’s announced $27.8 billion buyout of Horizon Therapeutics (HZNP) began to send Horizon’s shares tailspinning Monday evening into early today—and raises questions about how solidly merger-and-acquisition (M&A)...
MaxCyte joins the Alliance for mRNA Medicines (AMM) as a founding member
MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced that it has joined the Alliance...
The past, present and future of automation and digitalization in the life sciences laboratory
Sponsored Content by TecanDec 5 2023Reviewed by Olivia Frost
Thought LeadersKlaus Lun, Executive Vice President, Tecan and Chris Mason, Professor, Weill Cornell Medical College In this interview, we talk about the past, present, and future of automation and...
